$20.86
+0.13 (+0.63%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ODTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional
Held by 7 tracked-famous managers (HHLR ADVISORS, LTD., MARSHALL WACE, LLP, Balyasny Asset Management L.P., CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, +2 more) · FINRA short interest 9.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative ColitisNCT06850727Change in 3-component modified Mayo Clinic Score (MMCS) from baseline to after treatment with OD-07656Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Drug: OD-07656, Vedolizumab | Ulcerative Colitis (UC), UC - Ulcerative Colitis | 57 | Apr 2026 | 2026-02-11 |
| Phase 1 Study to Investigate OD-07656 in Healthy Adult ParticipantsNCT06206811Adverse event assessed by Safety review committeeRandomized · Single-masked · Treatment | Phase 1 | Completed | Drug: OD-07656 | Inflammatory Bowel Diseases, Blau Syndrome, Crohn Disease, Ulcerative Colitis, Spondyloarthritis | 101 | 2024-11-25actual | 2025-02-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19